DSpace
Universidad de Navarra

Dadun >
Depósito Académico >
CIMA (Centro de Investigación Médica Aplicada) >
Área de Neurociencias >
Neurofarmacología y conducta >
DA - CIMA - Neurociencias - Neurofarmacología y conducta - Artículos de Revista >

Statistics
Please use this identifier to cite or link to this item: http://hdl.handle.net/10171/18873

Title: Stress-induced anhedonia is associated to increased Alzheimer's disease markers
Author(s) : Briones, A. (A.)
Gagno, S. (S.)
Martisova, E. (E.)
Dobarro, M. (M.)
Aisa, B. (Bárbara)
Solas, M. (Maite)
Tordera, R.M. (Rosa María)
Ramirez, M. (María Javier)
Issue Date: 2012
Publisher: Wiley-Blackwell
Citation: Briones A, Gagno S, Martisova E, Dobarro M, Aisa B, Solas M, et al. Stress-induced anhedonia is associated to increased Alzheimer's disease markers. Br J Pharmacol 2012 Feb;165(4):897-907.
Keywords: Stress
Alzehimer´s disease
Venlafaxine
Abstract: Background and purpose: stress is believed to be associated with the development of neuropsychiatric disorders, including Alzheimer's disease (AD). We have studied mechanism implicated in vulnerability to stress and the relationship with changes in AD-related markers. Key results: when using the chronic mild stress (CMS) paradigm to induce anhedonia, 40% percent of rats were resistant to the development of anhedonia (CMSR), whereas the remaining were responsive (CMSA). Only CMSA rats displayed significant increases in immobility time in the forced swimming test, cognitive deficits in the novel object recognition test and significant decreases in synaptophysin, pAkt and pERK1/2 expression in the hippocampus. Increased levels of Aβ40, β-secretase (BACE1) and Tau phosphorylation were also found only in CMSA rats. Interestingly, all these effects in CMSA rats were reverted by normalization of the HPA axis activity by pharmacological treatment with the antidepressant venlafaxine. Conclusions and implications: It is proposed that vulnerability to stress might be related to development of AD pathology and that venlafaxine might be considered as a new therapeutical approach for the treatment of AD.
URI: http://hdl.handle.net/10171/18873
Publisher version (URL): http://bit.ly/oDPbCA
Appears in Collections:DA - CIMA - Neurociencias - Neurofarmacología y conducta - Artículos de Revista
DA - Farmacia - Farmacología - Artículos de revista

Files in This Item:

File Description SizeFormat
Farma2011.pdf993,33 kBAdobe PDFView/Open
Statistics

Import into RefWorks

SFX Query

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2010  Duraspace - Feedback